


## Beaumont Laboratory

# SARS-CoV-2 (CoVID-19) by NAA

Beaumont Laboratory is one of the first labs in Michigan to develop and offer a new test for Coronavirus.

To learn more about how Beaumont developed this innovative Coronavirus testing visit, [beaumont.org/covid-test](https://beaumont.org/covid-test)



### Order the following

- SARS-CoV-2 (CoVID-19) by NAA

### Beaumont Laboratory process

- COVID-19 testing may be performed in-house within 24 hours.
- COVID-19 test requests not completed in-house due to reagent availability will be sent out to a reference laboratory per protocol. Turn-around-time at reference laboratories varies.
- Positive COVID-19 results will be called to providers as they are received. Positive results will also be reported to MDHHS.

### Specimen collection criteria

Collect: one NP swab **only**.

### Collection and preparation for transport

- Nasopharyngeal (NP) in viral transport medium (i.e. M4-RT, M5, UVT, UTM) preferred.
- Maintain and transport all specimens refrigerated (2-8°C or 36-46°F).

### Rejection criteria

- dry swabs
- specimens in non-sterile or leaking containers
- specimens subjected to repeated freeze/thaw cycles

### In-lab processing

- Specimens are stable for eight (8) hours at room temperature (20-26°C or 68-78.8°F).
- Specimens may also be refrigerated (2-8°C or 36-46°F) prior to testing.

### Storage

Specimen stability for testing

- Room temperature: 8 hours
- Refrigerated (2-8°C or 36-46°F): 7 days
- Frozen (-20°C/-4°F or below): 7 days

Specimen storage in department prior to disposal

- Frozen (2-8°C or 36-46°F): 7 days.

### Laboratory

Clinical Molecular Pathology Lab Beaumont Hospital, Royal Oak and multiple Beaumont Microbiology Laboratory locations

### Performed

- Sunday through Saturday
- in-house results available within 24-48 hours

### Reference range

Not detected: No SARS-CoV-2 RNA detected.


*(continued on back)*

## Test methodology

Nucleic Acid Amplification. This test was developed and its performance characteristics determined by Beaumont Laboratory Clinical Molecular Pathology department, Royal Oak. It has not been cleared or approved by the U.S. FDA.

## Clinical utility

This assay aids in the detection of the SARS-CoV-2 (CoVID-19) novel Coronavirus. This assay detects the pathogen's RNA and does not rely upon the presence of infectious virus or seroconversion.



## Epidemiology

The 2019 novel Coronavirus SARS-CoV-2 was identified as the cause of an outbreak of respiratory illness first detected in December 2019 near Wuhan City, Hubei Province, China.

## Incubation period

According to estimates from the World Health Organization (WHO), the incubation period for SARS-CoV-2 ranges from two to 14 days with a median incubation period of five days.

## Transmission

The virus is thought to spread mainly from person-to-person.

- Between people who are in close contact with one another (within about six feet).
- Through respiratory droplets produced when an infected person coughs or sneezes.
- It may be possible that a person can get COVID-19 by touching a surface or object that has been recently contaminated by the virus and then touching their own mouth, nose, face, or possibly their eyes but this is not thought to be the main way the virus spreads.

## HCPCS Level II Codes

U0003



TO GET STARTED, CONTACT  
LABORATORY CUSTOMER  
SERVICE AT **800-551-0488**.

For more information or questions on SARS-CoV-2 (CoVID-19) analysis, please contact:

Clinical Molecular Pathology Lab  
Beaumont Hospital, Royal Oak

John Gibson, MS, CLSp(MB), SV(ASCP)  
Lab Manager, Molecular Diagnostics

Daniel A. Ortiz, Ph.D.  
Associate Director, Microbiology

**Community COVID-19 Hotline**  
**800-592-4784**

Please do not send patients to a Patient Service Center for collection for COVID-19 testing. Patients with questions should only call the hotline if they have COVID-19 symptoms: fever, dry cough and shortness of breath.